doxorubicin

Overview

Anthracycline topoisomerase II inhibitor; backbone of CHOP-based lymphoma regimens.

Evidence in the corpus

  • Component of CHOP/CHOEP/EPOCH/BV-CH(E)P regimens in 132 MSK nodal PTCL patients; TP53-mutated PTCL had median PFS 4.5 months vs 10.5 months for TP53-wildtype on doxorubicin-containing induction PMID:37078708.
  • In the UCLA sarcoma PDTO biobank (sarcoma_ucla_2024), doxorubicin was a component of the MAP neoadjuvant regimen (methotrexate/doxorubicin/cisplatin) tested in three treatment-naïve osteosarcoma biopsies; organoid residual viability after MAP correlated with post-resection necrosis and clinical recurrence. PMID:39305899
  • Doxorubicin is listed among NCCN-recommended regimens for osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma identified in the functional PDTO screen. PMID:39305899
  • NCI-60 CellMiner pharmacogenomics study examined ABCB1 (MDR1) expression as a determinant of doxorubicin sensitivity in colon cancer cell lines PMID:22802077
  • TCGA endometrial cancer analysis (2013) identifies ~25% of high-grade endometrioid tumors as copy-number-high serous-like and proposes chemotherapy (including doxorubicin) may be preferable to adjuvant radiotherapy for this molecular subgroup PMID:23636398
  • Cited in HCC systemic therapy review as historical reference chemotherapy; not a frontline standard given sorafenib/lenvatinib era PMID:24798001
  • Used as neoadjuvant monotherapy followed by ISG/SSG IV protocol (vincristine, doxorubicin, ifosfamide, etoposide) in a patient with EWSR1::BEND2 bladder sarcoma; intravesical tumor resolved but pelvic and lung metastases did not respond; patient switched to docetaxel + gemcitabine after nephrotoxicity PMID:28199314.

Resistance mechanisms

  • TP53 mutations and 17p deletions associate with inferior PFS on CHOP-based induction; CDKN2A deletion associates with inferior OS PMID:37078708.

Cancer types (linked)

  • PTCL, AITL, ALCL
  • OS — osteosarcoma; MAP regimen component; NCCN-listed in PDTO screen.
  • RMS, ES — rhabdomyosarcoma and Ewing sarcoma; NCCN-recommended regimen in the PDTO screen.

Sources

  • PMID:37078708
  • PMID:39305899 — Al Shihabi et al. (Cell Stem Cell 2024). UCLA sarcoma PDTO biobank; MAP regimen correlation with necrosis; NCCN-listed sarcoma standard-of-care.

This page was processed by crosslinker on 2026-05-09. - PMID:22802077

This page was processed by crosslinker on 2026-05-09. - PMID:23636398

This page was processed by crosslinker on 2026-05-09. - PMID:24798001

This page was processed by wiki-cli on 2026-05-11. - PMID:28199314

This page was processed by wiki-cli on 2026-05-14.